Biofrontera Stock Performance
| BFRI Stock | USD 0.93 0.01 1.09% |
On a scale of 0 to 100, Biofrontera holds a performance score of 5. The firm shows a Beta (market volatility) of 2.61, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biofrontera will likely underperform. Please check Biofrontera's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Biofrontera's price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biofrontera are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unfluctuating basic indicators, Biofrontera demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:20 | Last Split Date 2023-07-05 |
1 | Biofrontera Stock Drop Looks Sharp, But How Deep Can It Go - Trefis | 12/05/2025 |
2 | Biofrontera Received Notice of Noncompliance - TradingView Track All Markets | 01/07/2026 |
3 | Theres No Escaping Biofrontera Inc.s Muted Revenues Despite A 42 percent Share Price Rise | 01/23/2026 |
4 | Earnings Miss Will Biofrontera Inc stock go up in YEAR - July 2025 Rallies Community Trade Idea Sharing Platform - baoquankhu1.vn | 01/29/2026 |
5 | Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint | 02/09/2026 |
6 | Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz for Actinic Keratoses on Trunk and Extremities | 02/17/2026 |
7 | RenovaCare vs. Biofrontera Head-To-Head Review | 02/23/2026 |
| Begin Period Cash Flow | 1.5 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Relative Risk vs. Return Landscape
If you would invest 81.00 in Biofrontera on November 29, 2025 and sell it today you would earn a total of 12.00 from holding Biofrontera or generate 14.81% return on investment over 90 days. Biofrontera is currently generating 0.4232% in daily expected returns and assumes 6.4004% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Biofrontera, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biofrontera Target Price Odds to finish over Current Price
The tendency of Biofrontera Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.93 | 90 days | 0.93 | about 9.52 |
Based on a normal probability distribution, the odds of Biofrontera to move above the current price in 90 days from now is about 9.52 (This Biofrontera probability density function shows the probability of Biofrontera Stock to fall within a particular range of prices over 90 days) .
Biofrontera Price Density |
| Price |
Predictive Modules for Biofrontera
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biofrontera. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Biofrontera Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Biofrontera is not an exception. The market had few large corrections towards the Biofrontera's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Biofrontera, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Biofrontera within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.20 | |
β | Beta against Dow Jones | 2.61 | |
σ | Overall volatility | 0.08 | |
Ir | Information ratio | 0.06 |
Biofrontera Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biofrontera for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biofrontera can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Biofrontera had very high historical volatility over the last 90 days | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 23.94 M. | |
| Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: RenovaCare vs. Biofrontera Head-To-Head Review |
Biofrontera Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Biofrontera Stock often depends not only on the future outlook of the current and potential Biofrontera's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biofrontera's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.5 M | |
| Cash And Short Term Investments | 5.9 M |
Biofrontera Fundamentals Growth
Biofrontera Stock prices reflect investors' perceptions of the future prospects and financial health of Biofrontera, and Biofrontera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biofrontera Stock performance.
| Return On Equity | -11.92 | ||||
| Return On Asset | -0.65 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0.90) % | ||||
| Current Valuation | 12.14 M | ||||
| Shares Outstanding | 11.65 M | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 37.3 M | ||||
| Gross Profit | 23.94 M | ||||
| EBITDA | (14.44 M) | ||||
| Net Income | (17.76 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | (10.27 M) | ||||
| Earnings Per Share | (1.50) X | ||||
| Market Capitalization | 10.66 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (117.41 M) | ||||
| Working Capital | 8.68 M | ||||
About Biofrontera Performance
By evaluating Biofrontera's fundamental ratios, stakeholders can gain valuable insights into Biofrontera's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biofrontera has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biofrontera has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 149.93 | 229.60 | |
| Return On Tangible Assets | (0.93) | (0.97) | |
| Return On Capital Employed | (1.96) | (2.06) | |
| Return On Assets | (0.92) | (0.97) | |
| Return On Equity | (4.61) | (4.84) |
Things to note about Biofrontera performance evaluation
Checking the ongoing alerts about Biofrontera for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biofrontera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biofrontera had very high historical volatility over the last 90 days | |
| Biofrontera has some characteristics of a very speculative penny stock | |
| Biofrontera has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 37.3 M. Net Loss for the year was (17.76 M) with profit before overhead, payroll, taxes, and interest of 23.94 M. | |
| Biofrontera currently holds about 31.91 M in cash with (10.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Biofrontera has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: RenovaCare vs. Biofrontera Head-To-Head Review |
- Analyzing Biofrontera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biofrontera's stock is overvalued or undervalued compared to its peers.
- Examining Biofrontera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biofrontera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biofrontera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biofrontera's stock. These opinions can provide insight into Biofrontera's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biofrontera Stock analysis
When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |